{"nctId":"NCT03151434","briefTitle":"Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.","startDateStruct":{"date":"2017-02-07","type":"ACTUAL"},"conditions":["Video Assisted Thoracoscopic Surgery","Pain, Postoperative","Pain, Acute"],"count":147,"armGroups":[{"label":"Group #1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)"]},{"label":"Group #2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: US Guided Paravertebral Catheter (0.2% ropivicaine bolus)"]},{"label":"Group #3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Thoracic Epidural (0.125% bupivicaine/hydromorphone)"]}],"interventions":[{"name":"US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)","otherNames":["US Guided Single Shot Paravertebral Block"]},{"name":"US Guided Paravertebral Catheter (0.2% ropivicaine bolus)","otherNames":["US Guided Paravertebral Catheter"]},{"name":"Thoracic Epidural (0.125% bupivicaine/hydromorphone)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pt undergoing VATS procedure at Indiana University Hospital\n* ASA 1,2,3 or 4\n* Age 18 or older, male or female\n* Desires Regional anesthesia for postoperative pain control\n\nExclusion Criteria:\n\n* Any contraindication for Thoracic Epidural or Paravertebral block\n* History of substance abuse in the past 6 months\n* Patient staying intubated after surgery\n* Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours","description":"The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using \"units on a scale\" of 1-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours","description":"The VAS scores will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using\"units on a scale\" scale of 1-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours","description":"Opioid consumption will be collected by a study team member post operatively up to 3 days per protocol time requirements","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"21.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Average Nausea Scores Over 72 Hours","description":"Nausea scores will be collected by a study team member post operatively up to 3 days per protocol. Nausea will be recorded as 0=none, 1=mild, 2=moderate, or 3=severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.27","spread":null},{"groupId":"OG002","value":"0.29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Average Sedation Scores Over 72 Hours","description":"Sedation scores will be documented by a study team member post operatively up to 3 days per protocol requirements. Determining if patient is 0=awake and alert, 1=quietly awake, 2=asleep and arousable, or 3=deep sleep.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects Overall Satisfaction Scores","description":"Subjects will be followed up at 24 hours post operatively by a study team member to document patient overall satisfaction scores. Score was recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null},{"groupId":"OG001","value":"0.95","spread":null},{"groupId":"OG002","value":"1.33","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects Overall Satisfaction Scores","description":"Subjects will be followed up at 48 hours post operatively by a study team member to document patient overall satisfaction scores. Scores will be recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"1.05","spread":null},{"groupId":"OG002","value":"1.32","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}}